Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

RIPK1

  • Home
  • RIPK1
BIRC3 Gene Variants Disrupt RIPK1 Signaling, Driving Monogenic Crohn’s Disease: New Insights and Therapeutic Avenues
Posted inGastroenterology news

BIRC3 Gene Variants Disrupt RIPK1 Signaling, Driving Monogenic Crohn’s Disease: New Insights and Therapeutic Avenues

Posted by MedXY By MedXY 06/27/2026
Rare variants in the BIRC3 gene cause defective regulation of RIPK1 signaling, leading to increased intestinal epithelial cell death and monogenic Crohn's disease. Targeting RIPK1 offers a promising therapeutic strategy.
Read More
  • Evaluating Telehealth Stepped Alcohol Treatment to Reduce Alcohol Use in Chronic Liver Disease: Insights from a 2026 Randomized Controlled Trial
  • Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment
  • BIRC3 Gene Variants Disrupt RIPK1 Signaling, Driving Monogenic Crohn’s Disease: New Insights and Therapeutic Avenues
  • Successful Recanalization Boosts Functional Recovery in Minor Ischemic Stroke: Insights from the TEMPO-2 Trial
  • Distinct Early Cerebral Edema Subtypes as Predictors of Outcome in Cerebral Venous Thrombosis: Insights from the CLOT-VENUS Registry
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in